The findings from Fred Hutch Cancer Center suggest next step of exploring whether one dose of the vaccine is enough.

In the first meeting of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices (ACIP) ...

Merck on Tuesday issued full-year 2025 revenue ... The company said that sales range reflects a decision to halt shipments of ...

Leaders at Merck & Co. Inc. are facing a new derivative shareholder lawsuit over allegations that they made misleading ...

Rising competitive pressure on the diabetes franchise and persistent challenges for its human papillomavirus vaccine, Gardasil in China remain overhangs. There are concerns about Merck’s ability ...

Further, Merck’s earnings should grow faster as royalty payments on human papillomavirus vaccine Gardasil and Keytruda fall in 2024. Merck: Posts Leading Early-Stage Keytruda Data in Lung Cancer ...

Merck withdrew its previously issued long-term guidance of generating more than $11 billion in sales form Gardasil by 2030. Proquad, M-M-R II and Varivax vaccines recorded combined sales of $594 ...

Gardasil vaccine protects against cancer-causing human papilloma virus or HPV infections. The pause announcement comes a month after Merck received approval in China for use of the vaccine in males.